Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240040/S005

Oncomine Dx Express Test

Life Technologies Corporation · Decision date Sep 9, 2026

MEDTECHLEDGER EXPLANATIONP240040/S005

What did the FDA approve?

This FDA record documents the September 9, 2026 approval of supplement S005 to PMA P240040 for Life Technologies Corporation. The supplement, filed under the Panel Track with a labeling-change reason, expands the approved indications for use to add a companion diagnostic indication. That indication covers detection of ERBB2/HER2 activating mutations, specified as single nucleotide variants in exons 18–21 within the tyrosine kinase domain plus exon 20 insertions, in patients with non-small cell lung cancer.

The changed item is the indications statement of the device, a next-generation sequencing oncology panel for somatic or germline variant detection under product code PQP and the Pathology specialty. The source statement links the added indication to identifying NSCLC patients who may benefit from treatment with HYRNUO (sevabertinib). This supplement modifies the existing P240040 approval rather than approving the whole system anew; the record does not describe the panel's other content, performance characteristics, or original scope beyond the identifier.

FDA approval order statement

Approval to expand the indications for use to include a companion diagnostic (CDx) indication for the detection of ERBB2/HER2 activating mutations (SNVs in exons 18-21 within the tyrosine kinase domain and exon 20 insertions) in patients with non-small cell lung cancer (NSCLC) who may benefit from treatment with HYRNUO (sevabertinib).
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Pathology
Decision date
Sep 9, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240040/S005
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
APPR
Decision date
Sep 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

For the original device and its historical approval scope, see PMA P240040. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240040 · Original PMA

    Oncomine Dx Express Test

  2. P240040/S005 received

    Application receipt date recorded by FDA.

  3. P240040/S005 · FDA decision

    Panel Track

  4. P240040/S008 · Related supplement

    Oncomine Dx Express Test

Timeline entries are records held by MedtechLedger for P240040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240040

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA approvalJul 2, 2025FDA
Life Technologies CorporationPMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Life Technologies Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7335 Executive Way, Frederick, MD, 21704

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records